This interview with Andres Gomez-Emilsson is about 45 minutes too long and the title is misleading, but there are some interesting tidbits, observations, and speculation about the #phenomenology of #psychedelic experiences here.
This interview with Andres Gomez-Emilsson is about 45 minutes too long and the title is misleading, but there are some interesting tidbits, observations, and speculation about the #phenomenology of #psychedelic experiences here.
After decades of limited progress in depression treatment, recent advancements have sparked renewed interest in developing novel antidepressants, particularly rapid-acting antidepressants (RAADs). Despite these promising developments, there remains a significant gap in research on bipolar depression …
The study is the first of its kind to assess the effects of 5-MeO-DMT in the human brain and will investigate the neurophysiological effects of BPL-003, Beckley Psytech’s novel synthetic intranasal formulation of the psychedelic 5-MeO-DMT. In the study, healthy volunteers will be given both placebo and a 12 mg dose of BPL-003 on separate study visits over a period of 1 month while undergoing a high-density electroencephalogram (HD-EEG) scan to measure the electrical activity in the brain in order to better understand how 5-MeO-DMT elicits its profound consciousness-altering effects. The trial is being overseen by Dr. Christopher Timmermann and Dr David Errtizoe from the Centre for Psychedelic Research at Imperial College London and is funded through a research grant from Beckley Psytech. Initial results are expected in 2026.
Detailed analyses of the serotonin receptor 5-HT1A and the psychedelic 5-methoxy-N,N-dimethyltryptamine reveal the differences in receptor structural pharmacology that mediate signalling specificity, efficacy and potency, findings that may facilitate the development of new neuropsychiatric therapeutics.
The power of US Collective research exploring the unlimited potential of psychedelics Unlimited Sciences is a nonprofit organization that conducts real-world psychedelic research and provides cost-free direct support to those wanting to learn more about psychedelics. We believe everyone should be empowered to safely take their health into their own hands. Whether you’re seeking help, […]
cross-posted from: https://lemmy.world/post/12482573 [https://lemmy.world/post/12482573] > The dominant factor spanned a continuum of experiential facets whose opposite extreme flagged words that appear to describe mental expansion, including the terms universe, space, world, consciousness, breakthrough, existence, earth, dimension, reality, flame, and tunnel—all of which would be consistent with the phenomenology of the mystical experience (3). References to liminal conscious beings, also characteristic of the mystical experience, were described by the terms entity, sitter, alien, beings, and spirit. A theme of immediate time horizon was indicated by the term seconds and also suggested by references to bodily systems such as eyes and lungs, along with physiological functions inhale(d), exhaled, and breath. At the level of neurotransmitter receptors, this constellation of induced conscious alterations was linked most strongly with drugs that preferentially bind to D1, 5-HT7, KOR, 5-HT5A, as well as Sigma-1 and NMDA. The codependencies embedded in this profile of receptor bindings and subjective terms were most closely associated with the hallucinogenic drugs DMT, salvinorin A, 5-MeO-DMT, and ketamine. The anatomical brain regions that coexpress these sets of receptor density proxies included some of the highest regions of the association cortex, especially the rostral and dorsal anterior cingulate cortex, temporoparietal junction, and also prominently in the primary motor and sensory cortices. >